New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm

Zhang, Xiang; Sun, Jiewen; Yang, Min; Wang, Lei; Jin, Jie

doi:10.1016/j.critrevonc.2020.102928

Cited by 17 publications

(12 citation statements)

References 97 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the same way, a positivity for CD56, but negativity for CD3, removed the possibility of T-NK lymphocyte involvement; and negativity for CD34 excluded the presence of myeloid cells 5 . Immunohistochemistry showed CD4+, CD56 +, in addition to 2 positive dendritic cell markers (CD123 and TCL1) which allowed confirmation of the diagnosis 9 .Other dendritic cell markers not tested in this case are CD68, CD123 and BDCA-2/CD303 10 .…”

Section: Discussionmentioning

confidence: 56%

Blastic Plasmacytoid Dendritic Cell Neoplasm in a pediatric Peruvian patient

Tanchiva

Guevara

2020

Preprint

View full text Add to dashboard Cite

Blastic plasmacytoid dendritic cell neoplasm is an aggressive and rare hematologic malignancy, exceptionally presented in children. This case reports an 11-year-old Peruvian boy, with a 2-year history of a purple-violate tumor in a leg, lymph node involvement, and histopathological study with immunohistochemistry: CD4+, CD56+, Tdt+, CD45+, TCL1+. An institutional treatment protocol for high-risk ALL was given. There was a diagnosis delay in a pediatric patient with a rare but very visible neoplasm in a low-middle income country. Despite this, the clinical course was of an indolent evolution. The institutional protocol was efficient to achieve complete oncological disease response.

show abstract

Section: Discussionmentioning

confidence: 56%

Blastic Plasmacytoid Dendritic Cell Neoplasm in a pediatric Peruvian patient

Tanchiva

Guevara

2020

Preprint

View full text Add to dashboard Cite

show abstract

“…In the same way, a positivity for CD56, but negativity for CD3, removed the possibility of T-NK lymphocyte involvement; and negativity for CD34 excluded the presence of myeloid cells [6] . Immunohistochemistry showed CD4+, CD56 +, in addition to 2 positive dendritic cell markers (CD123 and TCL1) which allowed confirmation of the diagnosis [13] . Other dendritic cell markers not tested in this case are CD68, CD123 and BDCA-2/CD303 [14] .…”

Section: Case Reportmentioning

confidence: 86%

A case report of blastic plasmacytoid dendritic cell neoplasm in a hispanic child

Tanchiva

Chavez

Guevara

et al. 2021

Leukemia Research Reports

View full text Add to dashboard Cite

Plasmacytoid dendritic cell neoplasms are aggressive and rare hematologic malignancies characterized by clonal expansion of plasmacytoid dendritic cells with frequent cutaneous involvement. The pathogenesis is not well established, and it shows enhanced expression of CD56, CD4 and CD123 detected by flow cytometry and immunohistochemistry. We report a case report of this rare disease in a hispanic child with complete remission after using a protocol for high-risk acute lymphoblastic leukemia.

show abstract

“…Genetic mutations involving TET2, ASXL1, NRAS, and ATM were common, and less common mutations included NPM1, IKZF, KRAS, IDH2, MET, APC, BRAF, KIT, MLH1, RB1, RET, TP53, ZEB2, HOXB9, UBZ2, SRSF2, and VHL [61][62][63] . Recently, rearrangement of MYC on 8q24 (in 38% of patients with BPDCN) or a balanced translocation t(6;8) (p21;q24) has been reported [64,65] , and a high rate of monoallelic and biallelic 12p13/ ETV6 deletions was identified in BPDCN tumors and in the bone marrow of patients with BPDCN without detectable disease, indicating that such alterations may be involved in pathogenesis [66,67] .…”

Section: Chromosomal Abnormalities and Genetic Mutations Of Bpdcnmentioning

confidence: 99%

Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches

Cheng

Tang

et al. 2021

CURR MED SCI

View full text Add to dashboard Cite

SummaryBlastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematological malignancy characterized by recurrent skin nodules, an aggressive clinical course with rapid involvement of hematological organs, and a poor prognosis with poor overall survival. BPDCN is derived from plasmacytoid dendritic cells (pDCs) and its pathogenesis is unclear. The tumor cells show aberrant expression of CD4, CD56, interleukin-3 receptor alpha chain (CD123), blood dendritic cell antigen 2 (BDCA 2/CD303), blood dendritic cell antigen 4 (BDCA4) and transcription factor (E protein) E2-2 (TCF4). The best treatment drugs are based on experience by adopting those used for either leukemia or lymphoma. Relapse with drug resistance generally occurs quickly. Stem cell transplantation after the first complete remission is recommended and tagraxofusp is the first targeted therapy. In this review, we summarize the differentiation of BPDCN from its cell origin, its connection with normal pDCs, clinical characteristics, genetic mutations and advances in treatment of BPDCN. This review provides insights into the mechanisms of and new therapeutic approaches for BPDCN.

show abstract

New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm

Cited by 17 publications

References 97 publications

Blastic Plasmacytoid Dendritic Cell Neoplasm in a pediatric Peruvian patient

Blastic Plasmacytoid Dendritic Cell Neoplasm in a pediatric Peruvian patient

A case report of blastic plasmacytoid dendritic cell neoplasm in a hispanic child

Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches

Contact Info

Product

Resources

About